Outcomes and Healthcare Resource Utilisation in Adults With von Willebrand Disease Receiving On‐Demand Recombinant von Willebrand Factor in the United Kingdom
European Journal of Haematology · 2026
DOI: 10.1111/ejh.70032 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, 2026. Verfasst von Mike Laffan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Haematology, Imperial College London, Hammersmith Hospital, London, UK. Hauptthemen laut MEDLINE: von Willebrand Diseases, von Willebrand Factor, Patient Acceptance of Health Care, Health Resources. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda UK Ltd.
Abstract (Originalsprache)
Objectives
We describe treatment outcomes and healthcare resource utilisation (HCRU) in adults with von Willebrand disease (VWD) treated on demand with recombinant von Willebrand factor (rVWF) in the United Kingdom.
Methods
Retrospective chart review of adults (≥ 18 years) with congenital VWD receiving first‐time rVWF for the on‐demand treatment of spontaneous/traumatic bleeds, or the prevention/treatment of surgical bleeds, between 1 October 2020 and 30 June 2022 at seven hospitals. Treatment, outcome and VWD‐related HCRU data associated with the on‐demand treatment of all recorded bleeds were collected at first (index) treatment, for 12 months pre‐index and 3–12 months post‐index.
Results
Twelve patients (91.7% female and White/Caucasian, mean age 34.2 years) were treated on demand with rVWF at index: bleed resolution was achieved for all bleeds with limited requirement for additional treatments, no treatment switches, and no complications reported. Physician‐rated treatment satisfaction was ‘excellent’ (82.6%) or ‘good’ (17.4%) for all recorded on‐demand rVWF‐treated bleeds ( n = 23). Patients receiving any on‐demand treatment required an inpatient admission and ≥ 1 outpatient visit in 33.7% and 66.7% of cases, respectively.
Conclusions
Results support the effectiveness and safety profile of on‐demand rVWF treatment for spontaneous/traumatic bleeds in adults with VWD, adding to the growing body of evidence for rVWF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Haematology, Imperial College London, Hammersmith Hospital, London, UK.
- Takeda UK Ltd., London, UK.
- HCD Economics, UK.
ORCID-Profile: Oliver Heard
Förderung
- Takeda UK Ltd
Zitieren
APA
Laffan, M., Howitt, H., Jones, C., Brighton, S., Willock, R., Sanigorska, A., & Heard, O. (2026). Outcomes and Healthcare Resource Utilisation in Adults With von Willebrand Disease Receiving On‐Demand Recombinant von Willebrand Factor in the United Kingdom. European Journal of Haematology. https://doi.org/10.1111/ejh.70032
Vancouver
Laffan M, Howitt H, Jones C, Brighton S, Willock R, Sanigorska A, et al. Outcomes and Healthcare Resource Utilisation in Adults With von Willebrand Disease Receiving On‐Demand Recombinant von Willebrand Factor in the United Kingdom. European Journal of Haematology. 2026. doi:10.1111/ejh.70032
BibTeX
@article{Laffan2026,
author = {Laffan, Mike and Howitt, Heena and Jones, Cheryl and Brighton, Sarah and Willock, Rosa and Sanigorska, Anna and Heard, Oliver},
title = {Outcomes and Healthcare Resource Utilisation in Adults With von Willebrand Disease Receiving On‐Demand Recombinant von Willebrand Factor in the United Kingdom},
journal = {European Journal of Haematology},
year = {2026},
doi = {10.1111/ejh.70032}
}
EUVIMED